1. Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society
- Author
-
Hisahiro Matsubara, Kenji Nemoto, Shohei Kawashiro, Yasushi Toh, Takashi Uno, Yuji Tachimori, Keiichi Jingu, and Hodaka Numasaki
- Subjects
Adult ,Male ,medicine.medical_specialty ,Esophageal Neoplasms ,medicine.medical_treatment ,Esophageal cancer ,Thoracic Cavity ,Subgroup analysis ,Radiotherapy dose ,Gastroenterology ,03 medical and health sciences ,Esophagus ,0302 clinical medicine ,Japan ,Surgical oncology ,Internal medicine ,Humans ,Medicine ,Registries ,Aged ,Data Management ,Neoplasm Staging ,Aged, 80 and over ,business.industry ,Significant difference ,Radiotherapy Dosage ,Chemoradiotherapy ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Concurrent chemoradiotherapy ,Survival Rate ,Radiation therapy ,Cardiothoracic surgery ,030220 oncology & carcinogenesis ,Female ,Original Article ,030211 gastroenterology & hepatology ,business ,Nationwide survey ,Thoracic esophageal cancer - Abstract
Background In definitive chemoradiotherapy (CRTx) for esophageal cancer, a radiotherapy (RT) dose of 50.4 Gy in 28 fractions has been the standard in many countries, while 60 Gy in 30 fractions has been frequently used in Japan. To clarify the optimal RT dose in CRTx for esophageal cancer, we compared clinical outcomes with the two doses using data from the Comprehensive Registry of Esophageal Cancer in Japan by the Japan Esophageal Society (JES). Methods Of the patients enrolled in the registry for 2015–2017 surveys (patients treated between 2009 and 2011), 996 patients who received definitive CRTx with 50.4 Gy or 60 Gy for thoracic esophageal cancer were eligible for analysis. Results The complete response (CR) rates in the 50.4 Gy and 60 Gy groups were 49.1% and 46.4%, respectively (p = 0.5851). The 5-year overall survival (OS) rates in the 50.4 Gy group and 60 Gy group for stages I, II/III and IV were 64.2% and 57.2%, 35.0% and 27.0%, and 18.0% and 15.3%, respectively. Since no significant difference was found between the two groups, the 50.4 Gy group was not inferior to the 60 Gy group with regard to OS. Conclusions The analysis revealed that the 50.4 Gy group had a non-inferior outcome in comparison with the 60 Gy group for stages I, II/III and IV thoracic esophageal cancer. These results were obtained from a large database for the first time in Japan.
- Published
- 2020
- Full Text
- View/download PDF